Treats fascioliasis. Sold as Egaten. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Triclabendazole (sold as Egaten), first approved Feb 13, 2019, with 0 new uses approved and 0 published complete response letters.
| Study | Phase | Status | Posted |
|---|---|---|---|
| One and Two Doses of Oxfendazole Versus a Schedule of Two Doses of Triclabendazole in Chronic FascioliasisFascioliasis · Universidad Peruana Cayetano Heredia | Phase 2 | Not yet recruiting | Apr 16, 2024 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Novartis